Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder

References

• AltamuraACDrug-resistance phenomena in major psychoses:their discrimination and causal mechanismsClin Neuropharmacol199013S1151974169
   PubMed Web of Science ®Google Scholar
• AltamuraACA multidimentional (pharmacokinetic and clinical-biological) approach to neuroleptic response in SchizophreniaSchizophrenia Res1992818798
   Web of Science ®Google Scholar
• AltamuraACBobesJCunninghamDSchizophrenia: diagnosis and continuing treatment. Principles of practice from the European Expert Panel on the Contemporary Treatment of SchizophreniaInt J Psych Clin Pract2000Suppl 1111
   PubMedGoogle Scholar
• AltamuraACBoboVBMeltzerHYFactors affecting outcome in Schizophrenia and their relevance for psychopharmacological treatmentInt Clin Psychopharmacol2007222496717690594
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHFariesDEZhuBMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry2006674536016649833
   PubMed Web of Science ®Google Scholar
• BaethgeCBaldessariniRJMathiske-SchmidtKLong-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patientsJ Clin Psychiatry2005661748215705002
   PubMed Web of Science ®Google Scholar
• BerkMDoddSCallalyPHistory of illness prior to a diagnosis of bipolar disorder or schizoaffective disorderJ Affect Disord20072323
   Google Scholar
• BowdenCLPredictors of response to divalproex and lithiumJ Clin Psychiatry19955625307883739
   PubMed Web of Science ®Google Scholar
• BowdenCLCollinsMAMcElroySLRelationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placeboNeuropsychopharmacology2005301932915956987
   PubMed Web of Science ®Google Scholar
• BowdenCLSwannACCalabreseJRA randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute maniaJ Clin Psychiatry20066715011017107240
   PubMed Web of Science ®Google Scholar
• CalabreseJRDelucchiGASpectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorderAm J Psychiatry199014743142107762
   PubMed Web of Science ®Google Scholar
• CalabreseJRSheltonMDRapportDJA 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorderAm J Psychiatry200516221526116263857
   PubMed Web of Science ®Google Scholar
• ChangKDKetterTASpecial issues in the treatment of paediatric bipolar disorderExpert Opin Pharmacother200126132211336611
   PubMedGoogle Scholar
• ChuePKovacsCSSafety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and managementBipolar Disord20035627914700015
   PubMed Web of Science ®Google Scholar
• ClatworthyJBowskillRRankTAdherence to medication in bipolar disorder: a qualitative study exploring the role of patients’ beliefs about the condition and its treatmentBipolar Disord200796566417845282
   PubMed Web of Science ®Google Scholar
• da RochaFFSoaresFMCorreaHAddition of lamotrigine to valproic acid: A successful outcome in a case of rapid-cycling bipolar affective disorderProg Neuropsychopharmacol Biol Psychiatry20073115489 Epub 2007 Jun 2217630063
   PubMed Web of Science ®Google Scholar
• DavisJMChenNGlickIDA meta-analysis of the efficacy of second-generation antipsychoticsArch Gen Psychiatry2003605536412796218
   PubMed Web of Science ®Google Scholar
• DolderCRLacroJPDunnLBAntipsychotic medication adherence: is there a difference between typical and atypical agents?Am J Psychiatry2002159103811772697
   PubMed Web of Science ®Google Scholar
• DunnerDLFieveRRClinical factors in lithium carbonate prophylaxis failureArch Gen Psychiatry197430229334589148
   PubMed Web of Science ®Google Scholar
• FentonWSBlylerCRHeinssenRKDeterminants of medication compliance in schizophrenia: empirical and clinical findingsSchizophr Bull199723637519366000
   PubMed Web of Science ®Google Scholar
• GeddesJFreemantleNHarrisonPAtypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysisBMJ20003211371611099280
   PubMed Web of Science ®Google Scholar
• GhaemiSNGoodwinFKLong-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant useJ Affect Disord200165281711511408
   PubMed Web of Science ®Google Scholar
• GoldbergJFPerlisRHGhaemiSNAdjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BDAm J Psychiatry200716413485517728419
   PubMed Web of Science ®Google Scholar
• GrayRWykesTGournayKFrom compliance to concordance:a review of the literature on interventions to enhance compliance with antipsychotic medicationJ Psychiatr Ment Health Nurs200292778412060371
   PubMedGoogle Scholar
• HantoucheEGAkiskalHSAzorinJMClinical and psychometric characterization of depression in mixed mania: a report from the French National Cohort of 1090 manic patientsJ Affect Disord2006962253216427703
   PubMed Web of Science ®Google Scholar
• Herrera-EstrellaMApiquianRFresanAThe effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label studyBMC Psychiatry200552215869707
   PubMed Web of Science ®Google Scholar
• JoycePRCarbamazepine in rapid cycling bipolar affective disorderInt Clin Psychopharmacol1988312393397520
   PubMed Web of Science ®Google Scholar
• KimSWShinISKimJMAmisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trialProg Neuropsychopharmacol Biol Psychiatry20073115049 Epub 2007 Jul 1317692448
   PubMed Web of Science ®Google Scholar
• LecrubierYQuintinPBouhassiraMThe treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trialActa Psychiatr Scand20061143192717022791
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353120923 Epub 2005 Sep 1916172203
   PubMed Web of Science ®Google Scholar
• LindenMEichFXPyrkoschLDo differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulprideInt Clin Psychopharmacol200722175817414744
   PubMed Web of Science ®Google Scholar
• LindenMScheelTEichFXImprovement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulprideJ Psychopharmacol20062081523 Epub 2006 Jan 916401647
   PubMed Web of Science ®Google Scholar
• McElroySLKeck PEJrPope HGJrValproate in the treatment of rapid-cycling bipolar disorderJ Clin Psychopharmacol1988827593145291
   PubMed Web of Science ®Google Scholar
• MajMMaglianoLPirozziRValidity of rapid cycling as a course specifier for bipolar disorderAm J Psychiatry1994151101598010357
   PubMed Web of Science ®Google Scholar
• MasiGMucciMPariCChildren with schizophrenia: clinical picture and pharmacological treatmentCNS Drugs2006208416616999454
   PubMed Web of Science ®Google Scholar
• MeyerJMKoroCEThe effects of antipsychotic therapy on serum lipids: a comprehensive reviewSchizophr Res20047011715246458
   PubMed Web of Science ®Google Scholar
• MortimerAMHow do we choose between atypical antipsychotics? The advantages of amisulprideInt J Neuropsychopharmacol20047S21514972081
   PubMed Web of Science ®Google Scholar
• MortimerAMartinSLooHA double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophreniaInt Clin Psychopharmacol20041963915076013
   PubMed Web of Science ®Google Scholar
• MortimerAWilliamsPMeddisDImpact of side-effects of atypical antipsychotics on non-compliance, relapse and costJ Int Med Res2003311889612870371
   PubMed Web of Science ®Google Scholar
• MullerMJWetzelHBenkertODifferential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysisInt Clin Psychopharmacol2002172496112177587
   PubMed Web of Science ®Google Scholar
• MurphyBPStuartAHWadeDEfficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot studyHum Psychopharmacol200621511717066489
   PubMed Web of Science ®Google Scholar
• NaberDKarowAGood tolerability equals good results: the patient’s perspectiveEur Neuropsychopharmacol200111S391611587886
   PubMed Web of Science ®Google Scholar
• NussPHummerMTessierCThe use of amisulpride in the treatment of acute psychosisTherapeutics and Clin Management20073311
   PubMedGoogle Scholar
• PapadimitriouGNCalabreseJRDikeosDGRapid cycling bipolar disorder: biology and pathogenesisInt J Neuropsychopharmacol2005828192 Epub 2005 Mar 115737249
   PubMed Web of Science ®Google Scholar
• PeuskensJSwitching to amisulprideCurr Med Res Opin200218s23812418609
   PubMed Web of Science ®Google Scholar
• PeuskensJDe HertMMortimerAMetabolic control in patients with schizophrenia treated with amisulpride or olanzapineInt Clin Psychopharmacol2007221455217414740
   PubMed Web of Science ®Google Scholar
• PeuskensJMollerHJPuechAAmisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidoneEur Neuropsychopharmacol2002123051012126869
   PubMed Web of Science ®Google Scholar
• PostRUhdeTKramlingerKCarbamazepine treatment of mania: clinical and biochemical aspectsClin Neuropharmacol1986954793567962
   PubMed Web of Science ®Google Scholar
• RettenbacherMABurnsTKemmlerGSchizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medicationPharmacopsychiatry200437103915138893
   PubMed Web of Science ®Google Scholar
• SachsGSNierenbergAACalabreseJREffectiveness of adjunctive antidepressant treatment for bipolar depressionN Engl J Med2007356171122 Epub 2007 Mar 2817392295
   PubMed Web of Science ®Google Scholar
• SchneckCDTreatment of rapid-cycling bipolar disorderJ Clin Psychiatry20066722717029493
   PubMed Web of Science ®Google Scholar
• SechterDPeuskensJFleurotOAmisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind studyNeuropsychopharmacology20022710718112464464
   PubMed Web of Science ®Google Scholar
• SpellerJCBarnesTRCursonDAOne-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidolBr J Psychiatry199717156489519098
   PubMed Web of Science ®Google Scholar
• SpurlingRDLambertiJSOlsenDChanges in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart reviewJ Clin Psychiatry200768406917388710
   PubMed Web of Science ®Google Scholar
• SuppesTLeverichGSKeckPEThe Stanley Foundation Bipolar Treatment Outcome Network II. Demographics and illness characteristics of the first 261 patientsJ Affect Disord200167455911869752
   PubMed Web of Science ®Google Scholar
• SuppesTMintzJMcElroySLMixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenonArch Gen Psychiatry20056210899616203954
   PubMed Web of Science ®Google Scholar
• ThomasPThe stable patient with schizophrenia – from antipsychotic effectiveness to adherenceEur Neuropsychopharmacol200717S1152217336766
   PubMed Web of Science ®Google Scholar
• TondoLBaldessariniRJRapid cycling in women and men with bipolar manic-depressive disordersAm J Psychiatry1998155143469766777
   PubMed Web of Science ®Google Scholar
• TondoLHennenJBaldessariniRJRapid-cycling bipolar disorder:effects of long-term treatmentsActa Psychiatr Scand200310841412807371
   PubMed Web of Science ®Google Scholar
• WetzelHGrunderGHillertAAmisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study GroupPsychopharmacology (Berl)1998137223329682999
   PubMed Web of Science ®Google Scholar
• YoungCMFindlingRLPharmacologic treatment of adolescent and child schizophreniaExpert Rev Neurother20044536015853615
   PubMedGoogle Scholar